Arcus Biosciences, Inc. (RCUS)

Market Cap	2.34B +91.2%
Revenue (ttm)	240.00M -8.7%
Net Income	-341.00M
EPS	-3.39
Shares Out	123.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,449,353
Open	20.17
Previous Close	19.96
Day's Range	18.81 - 20.53
52-Week Range	6.50 - 26.40
Beta	0.84
Analysts	Buy
Price Target	28.22 (+49.15%)
Earnings Date	Feb 25, 2026

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical tria...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 15, 2018
• Employees: 627
• Stock Exchange: NYSE
• Ticker Symbol: RCUS
• Website: https://www.arcusbio.com

Financial Performance

In 2024, Arcus Biosciences's revenue was $258.00 million, an increase of 120.51% compared to the previous year's $117.00 million. Losses were -$283.00 million, -7.82% less than in 2023.

Analyst Summary

According to 9 analysts, the average rating for RCUS stock is "Buy." The 12-month stock price target is $28.22, which is an increase of 49.15% from the latest price.

Price Target

$28.22

(49.15% upside)

Analyst Consensus: Buy